Medical Supplies

Bruker Selected as ‘Company of the Year’ by Instrument Business Outlook

Retrieved on: 
Monday, April 1, 2024
Health, Science, Other Science, Research, Medical Supplies, CER, Culture, Growth, Project, EPS, Corporation, Spiral Dynamics, Operational excellence, Proteomics, BRKR

Bruker Corporation (NASDAQ: BRKR) has been selected as the Instrument Business Outlook (IBO) ‘Company of the Year’ for 2023.

Key Points: 
  • Bruker Corporation (NASDAQ: BRKR) has been selected as the Instrument Business Outlook (IBO) ‘Company of the Year’ for 2023.
  • IBO cited Bruker’s double-digit organic revenue growth in 2023 in all major regions, and in all business groups, demonstrating a transformed portfolio and operational strength.
  • The IBO recognition follows Bruker’s three consecutive years of double-digit organic revenue growth.
  • IBO is a publication of SDi, a division of Science and Medicine Group, which offers custom market research and strategic advisory services.

FIGS Releases Its 2023 Impact Report

Retrieved on: 
Monday, April 1, 2024
Specialty, Other Philanthropy, Environmental, Social and Governance (ESG), Environment, Fashion, Retail, Footwear, Environmental Issues, Professional Services, Health, Women, Philanthropy, DEI (Diversity, Equity and Inclusion), Men, Foundation, Nursing, Consumer, Medical Supplies, Supply Chain Management, Sustainability, Online Retail, Other Retail, Other Health, Organization, Entrepreneurship, Partnership, Female, Cancer, Mentorship, Black History Month, Water, Fire, Culture, Multimedia, Student National Medical Association

FIGS, Inc. (NYSE: FIGS), the global leading healthcare apparel brand dedicated to improving the lives of healthcare professionals, today released its 2023 Impact Report.

Key Points: 
  • FIGS, Inc. (NYSE: FIGS), the global leading healthcare apparel brand dedicated to improving the lives of healthcare professionals, today released its 2023 Impact Report.
  • The full FIGS 2023 Impact Report is available at wearfigs.com/impactreport and provides a comprehensive view into FIGS’ efforts to positively impact healthcare professionals.
  • View the full release here: https://www.businesswire.com/news/home/20240401113316/en/
    FIGS Releases 2023 Impact Report (Graphic: Business Wire)
    “Since day one, FIGS has been on a mission to improve the lives of healthcare workers globally,” said Trina Spear, Chief Executive Officer and Co-Founder.
  • Creating impact for our Awesome Humans, along with all of our stakeholders, is why we started FIGS and it’s what still drives us today.”
    Highlights of the FIGS 2023 Impact Report include:
    FIGS donated almost $600,000 to 17 organizations.

Clinical Collaboration Agreement between Teva and Launch Therapeutics to Accelerate Development of Dual-Action Asthma Rescue Inhaler (ICS-SABA/TEV-’248) Respiratory Program; Teva and Abingworth Enter Strategic Development Funding Agreement

Retrieved on: 
Monday, April 1, 2024
Other Health, Research, Professional Services, Pharmaceutical, Medical Devices, Clinical Trials, Science, Biotechnology, Medical Supplies, Finance, Other Science, Health, TEVA, U.S. FDA, MDPI, Fluticasone, Patient, Doctor of Philosophy, MD, Asthma, Therapy, Teva, Pharmaceutical industry

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Launch Therapeutics, Inc., today announced a clinical collaboration agreement to further accelerate the clinical research program of Teva’s ICS-SABA (TEV-‘248).

Key Points: 
  • Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Launch Therapeutics, Inc., today announced a clinical collaboration agreement to further accelerate the clinical research program of Teva’s ICS-SABA (TEV-‘248).
  • As part of the clinical collaboration agreement, Launch Therapeutics, a clinical development company backed by Abingworth and Carlyle, will have the lead role in the operational execution and management of the planned clinical trials, focused on accelerating Teva’s ICS-SABA (TEV-‘248) clinical research program.
  • Teva will recognize the funding as a reduction in research and development expenses and will retain full rights to the Company’s ICS/SABA program.
  • “Bridging together Teva's deep therapeutic expertise with Launch Therapeutics' profound clinical and operational expertise generates value to execute and accelerate this program.

Global Polymerase Chain Reaction (PCR) for qPCR, dPCR, Singleplex & Multiplex Markets, 2023-2024 and 2027: Disruption Looms, Syndromic Diagnostics Looks Unstoppable, The Instrumentation Curve - ResearchAndMarkets.com

Retrieved on: 
Friday, March 29, 2024
Science, Biotechnology, Research, Medical Supplies, General Health, Health, COVID-19, Medical Devices, Continue, PCR

6.21 Chelex-Based Protocol to Reduce Cost, Time for PCR Testing

Key Points: 

6.21 Chelex-Based Protocol to Reduce Cost, Time for PCR Testing
6.36 SARS- Testing Demand to Continue 'Through 2022, and Beyond'

Syndromic Multiplex Panels Market Research Report 2024: Global Analysis, Strategies, Trends and Forecasts to 2028 with Executive Guides - ResearchAndMarkets.com

Retrieved on: 
Friday, March 29, 2024
Medical Supplies, Medical Devices, Health, Technology, Infectious Diseases, Health Technology, PCR, Disease, POCT, SARS-CoV-2, RSV, DTC, BioMérieux, STI, Live

5.2.3 Infectious Disease is Declining But..

Key Points: 
  • 5.2.3 Infectious Disease is Declining But..
    5.2.5 Economic Growth improves Living Standards.
  • 5.3.14 Syndromics drives POCT adoption.
  • 6.2 BioMerieux Submits Application for Respiratory, Sore Throat Panel
    6.8 Altratech to Enter MDx, POC Space by Supplanting PCR
    6.21 Quidel Gains CE Mark for Savanna Analyzer, Respiratory Panel
    6.26 Binx Health Targeting Clinics, DTC & OTC With STI Tests
    6.27 Luminex Lands BARDA Grant to Develop Test for SARS-CoV-2, Flu, RSV
    6.29 MiRxes Receives Approval for Multiplex SARS-CoV-2, Flu Test

Retractable Technologies, Inc. Declares Dividends to Series II and III Class B Preferred Stock Shareholders

Retrieved on: 
Friday, March 29, 2024
General Health, Medical Devices, Other Health, Health, Medical Supplies, RVP, Risk, Injury, Bloodstream infections, Syringe, Injection, Safety, Online shopping

Retractable Technologies, Inc. (“Retractable”) (NYSE American: RVP) announced today that its Board of Directors has declared dividends to holders of its Series II Class B and Series III Class B Convertible Preferred Stock in the amounts of $39,050.00 and $18,561.25, respectively.

Key Points: 
  • Retractable Technologies, Inc. (“Retractable”) (NYSE American: RVP) announced today that its Board of Directors has declared dividends to holders of its Series II Class B and Series III Class B Convertible Preferred Stock in the amounts of $39,050.00 and $18,561.25, respectively.
  • The dividends cover the period beginning January 1, 2024 through March 31, 2024.
  • The dividends will be paid on April 22, 2024 to shareholders of record as of the close of business on April 10, 2024.
  • Retractable manufactures and markets VanishPoint® and Patient Safe® safety medical products and the EasyPoint® needle.

Retractable Technologies, Inc. Reports Results for 2023

Retrieved on: 
Friday, March 29, 2024
Medical Supplies, Health, Medical Devices, Other Health, COVID-19, General Health, Pharmaceutical, Workforce, Government, RVP, Vaccination, Pharmaceutical industry

Retractable Technologies, Inc. (NYSE American: RVP) reports the following information relating to the year ended December 31, 2023.

Key Points: 
  • Retractable Technologies, Inc. (NYSE American: RVP) reports the following information relating to the year ended December 31, 2023.
  • Our revenues for 2023 decreased 54.0% as domestic and international COVID-19 vaccination sales decreased.
  • Comparability of 2023 to 2020-2022 financial results is challenging due to the unusual volume of pandemic sales.
  • In 2022 and 2023, we reduced our workforce in an effort to reduce our expenses, but expenses remain higher than prior to 2020.

Medpace Holdings, Inc. to Report First Quarter 2024 Financial Results on April 22, 2024

Retrieved on: 
Thursday, March 28, 2024
Science, Other Science, Biotechnology, Pharmaceutical, Medical Supplies, Health, Medical Devices, Other Health, Telephone, Webcast

Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced that it will report its first quarter 2024 financial results after the market close on Monday, April 22, 2024.

Key Points: 
  • Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced that it will report its first quarter 2024 financial results after the market close on Monday, April 22, 2024.
  • The Company will host a conference call the following morning, Tuesday, April 23, 2024, at 9:00 a.m.
  • To participate in the conference call, interested parties must register in advance by clicking on this link .
  • A supplemental slide presentation will also be available at the “Investors” section of Medpace’s website prior to the start of the call.

Long-Acting Drug Delivery Technologies and Services Market, 2033: Patient-Centric Approaches Fueling Growth, Small Molecules Dominate, Biopharmaceutical and Life Science Companies Lead - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 28, 2024
Biotechnology, Medical Devices, Health, Pharmaceutical, Medical Supplies, Growth, Prevalence, End user, Conditional sentence, Polymer, Biopharmaceutical, Research, Overalls, Investment, Traction, Pharmaceutical industry

As of 2022, the global long-acting drug delivery technologies and services market held a value of $11.41 billion.

Key Points: 
  • As of 2022, the global long-acting drug delivery technologies and services market held a value of $11.41 billion.
  • The global long-acting drug delivery technologies and services market (by type of molecule delivered) was dominated by the small molecules segment in FY2022.
  • The Biopharmaceutical and Life science Companies segment accounted for the largest share of the global long-acting drug delivery technologies and services market (by End User) in FY2022.
  • Biopharmaceutical and life science companies are poised to sustain their dominant role in the global long-acting drug delivery technologies and services market as primary end users.